IPAB
IPAB or Independent Payment Advisory Board is a United States federal agency that was established by the Patient Protection and Affordable Care Act (PPACA) in 2010. The board is tasked with developing proposals to reduce the per capita rate of growth in Medicare spending.
History[edit | edit source]
The Independent Payment Advisory Board was created by the Patient Protection and Affordable Care Act, which was signed into law by President Barack Obama on March 23, 2010. The board was designed to serve as a check on the growth of Medicare spending.
Function[edit | edit source]
The primary function of the IPAB is to recommend policies to Congress to help slow the growth of national health care expenditures while preserving or enhancing the quality of care. If the Medicare program's per capita spending grows at a rate that is too high, the IPAB is required to make recommendations to reduce this growth rate.
Structure[edit | edit source]
The IPAB is composed of 15 full-time members who are appointed by the President of the United States and confirmed by the Senate. The members serve for six-year terms and can be reappointed. The board is required to include physicians and other health professionals, experts in the area of health finance, health services researchers, employers, and representatives of consumers and the elderly.
Criticism[edit | edit source]
The IPAB has been criticized for a variety of reasons. Some critics argue that the board has too much power and that its decisions could lead to rationing of care. Others argue that the board is not accountable enough to the public.
See also[edit | edit source]
- Medicare (United States)
- Patient Protection and Affordable Care Act
- Healthcare reform in the United States
References[edit | edit source]
External links[edit | edit source]
IPAB Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD